miRagen Therapeutics Exclusively Licenses Intellectual Property From the University of Glasgow for microRNA-145 Targeting in the Treatment of Pulmonary Arterial Hypertension

Published: Mar 05, 2013

BOULDER, Colo.--(BUSINESS WIRE)--miRagen Therapeutics, Inc., a biopharmaceutical company developing innovative microRNA (miRNA)-based therapeutics, and the University of Glasgow, a world-leader in cardiovascular research, announced today that they have signed an exclusive license agreement for intellectual property they developed as part of an ongoing collaboration for microRNA-145 in pulmonary arterial hypertension (PAH). This licensing agreement provides miRagen with exclusive rights to an important discovery made in collaboration with the University of Glasgow and the University of Cambridge, enabling miRagen to advance miR-145 inhibition as a potential therapeutic approach for PAH.

Back to news